GeoVax Executives Pursue European Partnerships to Advance Vaccine and Cancer Therapy Development
GeoVax Labs is intensifying European partnership efforts to accelerate development of vaccines for mpox, COVID-19, and cancer therapies, addressing critical global health needs.
GeoVax Labs, Inc. senior leadership will participate in key European meetings over the coming weeks to advance partnering discussions across the company's portfolio of vaccines and immunotherapies. Chairman and CEO David A. Dodd and Vice President John Sharkey, PhD, will lead the company's presence at World Vaccine Congress Europe in Amsterdam from October 14-16 and BIO-Europe Fall in Vienna from November 3-5.
The company's engagement strategy includes meetings with global health organizations including WHO, UNICEF, CEPI, Gavi, and the Africa CDC, alongside established and prospective academic collaborators across Europe. Dodd emphasized the company's focus on solidifying durable relationships that can accelerate development and expand access to critical vaccines and immunotherapies. The partnership discussions will center on near-term opportunities in mpox and smallpox preparedness, addressing unmet COVID-19 vaccine needs for immunocompromised patients, expanding Gedeptin® as neoadjuvant cancer therapy, and exploring complementary collaborations across the company's broader platform.
GeoVax's partnering focus spans multiple pipeline candidates and technology platforms. The GEO-MVA mpox and smallpox vaccine candidate represents a U.S.-based MVA program designed to accelerate access to a critically needed second-source vaccine with rapid, scalable manufacturing capabilities. The GEO-CM04S1 multi-antigen COVID-19 vaccine, designed to elicit robust T-cell and antibody responses, targets the estimated over 400 million immunocompromised patients worldwide who face current unmet vaccine needs. Gedeptin®, a tumor-targeted immuno-oncology approach, shows potential combination synergies with checkpoint inhibitors as a potential new neoadjuvant therapy against solid tumors.
Additional platform applications include hemorrhagic fever and Zika programs, along with continuous cell-line manufacturing and potential technology-transfer collaborations. Dr. Sharkey noted that the company continues to receive compelling interest from governments, NGOs, and potential industry collaborators seeking diversified, resilient vaccine supply and clinically differentiated immunotherapies. The company's goal is to convert this interest into structured collaborations that accelerate development, manufacturing readiness, and regional availability. Additional information about GeoVax and its programs is available at https://www.geovax.com.